Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study

被引：0
|
作者：
Shi, Y-K. [1 ]
Gao, L. [2 ]
Tian, Y. [3 ]
Chen, J. [4 ]
Wang, J. [3 ]
Bai, C. [5 ]
Li, X. [6 ]
Su, H. [7 ]
Liu, Z. [8 ]
机构：
[1] Chinese Acad Med Sci, Natl Canc Ctr, Canc Hosp, Med Oncol Dept, Beijing, Peoples R China
[2] Gansu Prov Canc Hosp, Dept Radiotherapy, Lanzhou, Peoples R China
[3] Gansu Prov Canc Hosp, Head & Neck Serv, Lanzhou, Peoples R China
[4] Cent South Univ, Xiangya Med Sch, Hunan Canc Hosp, Dept Thorac Surg 1, Changsha, Peoples R China
[5] Peking Union Med Coll Hosp, Dept Med Oncol, Beijing, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Oncol Dept, Zhengzhou, Peoples R China
[7] Fourth Mil Med Univ, Tangdu Hosp, Oncol Dept, Xian, Peoples R China
[8] Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Oncol, Dept Head & Neck Serv, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
908P
引用
收藏
页码：S806 / S806
页数：1
相关论文
共 50 条
  • [1] A phase II study cohort of penpulimab plus anlotinib in patients with recurrent or metastatic non-squamous cell carcinomas of head and neck
    Zhang, Changgong
    Sun, Yan
    Wang, Jun
    Liu, Zhigang
    Su, Haichuan
    Chen, Jianhua
    Tian, Youxin
    Wu, Huijuan
    Gao, Liying
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC).
    Scheff, Nicole N.
    Nilsen, Marci Lee
    Li, Jinhong
    Harris, Alexandria L.
    Swartz, Andrew
    Hsieh, Ronan Wenhan
    Anderson, Jennifer Lynn
    Ferris, Robert L.
    Menk, Ashley
    Delgoffe, Greg M.
    Zandberg, Dan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] A phase II study of pemetrexed (P) plus gemcitabine (G) in patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Pfister, D. G.
    Haque, S.
    Stambuk, H.
    Lisa, D. M.
    Shen, R.
    Carlson, D.
    Fury, M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Preliminary efficacy and safety of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase II clinical trial.
    Ji, Dongmei
    Sang, Youzhou
    Liu, Xin
    Guo, Yanjing
    Yang, Yanan
    Chen, Guangliang
    Dong, Shu
    Wang, Yulong
    He, Xiayun
    Ying, Hongmei
    Lu, Xueguan
    Wang, Yu
    Hu, Chaosu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
    Ho, A. L.
    Adkins, D. R.
    Hanna, G. J.
    Bruce, J.
    Ahn, M. J.
    Docampo, L. Iglesias
    Kang, H.
    Wong, D. J.
    Psyrri, A.
    Gillison, M.
    Brana, I.
    Liu, Y. C.
    Hsieh, C. Y.
    Hong, M. H.
    Zhang, Z.
    Balsara, B.
    Saunders, A.
    Hernandez, A. Gasco
    Dale, S.
    Haddad, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
  • [6] A phase I/Ib study of lenvatinib and cetuximab in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Dunn, Lara
    Ho, Alan Loh
    Eng, Juliana
    Michel, Loren S.
    Fetten, James Vincent
    Warner, Elizabeth
    Kriplani, Anuja
    Zhi, Wanqing Iris
    Ng, Kenneth K.
    Haque, Sofia
    Pfister, David G.
    Sherman, Eric Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Fury, Matthew G.
    Sherman, Eric
    Ho, Alan
    Katabi, Nora
    Sima, Camelia
    Kelly, Katherine W.
    Nwankwo, Oby
    Haque, Sofia
    Pfister, David G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 121 - 128
  • [8] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G. Fury
    Eric Sherman
    Alan Ho
    Nora Katabi
    Camelia Sima
    Katherine W. Kelly
    Oby Nwankwo
    Sofia Haque
    David G. Pfister
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 121 - 128
  • [9] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study
    Chung, Christine
    Bonomi, Marcelo
    Steuer, Conor
    Schell, Michael
    Li, Jiannong
    Johnson, Matthew
    McMullen, Caitlin
    Wadsworth, J. Trad
    Patel, Krupal
    Kish, Julie
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James
    Saba, Nabil
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [10] POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
    Forster, M. D.
    Mason, J.
    Moleron, R.
    Sacco, J. J.
    Beasley, M.
    Ferreira, M. Reis
    Srinivasan, D.
    Yip, K.
    Stewart, G.
    Chiu, K.
    Ward, A.
    Metcalf, R.
    Adedoyin, T.
    Begum, R.
    Chiwewe, M.
    Poole, K.
    Spanswick, V.
    Pathak, Y.
    Counsell, N.
    Rashid, M. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S623 - S624
12345